胺碘酮联合参松养心胶囊用于冠心病心律失常临床观察及安全性分析.docVIP

胺碘酮联合参松养心胶囊用于冠心病心律失常临床观察及安全性分析 　　【摘要】 目的：探讨胺碘酮联合参松养心胶囊用于冠心病心律失常的临床观察及安全性。方法：选取2013年1月-2016年12月本院收治的冠心病心律失常患者120例，按照治疗方法不同将其分为对照组和研究组，各60例。对照组采用胺碘酮治疗，研究组在对照组基础上加用参松养心胶囊。比较两组治疗前后心功能指标、心律失常的改善情况及不良反应。结果：治疗后，两组心搏出量（SV）、心输出量（CO）、心脏指数（CI）及射血分数（EF）均优于治疗前，且研究组均优于对照组，比较差异均有统计学意义（P0.05）；研究组不良反应发生率为5.0%，少于对照组的26.7%，比较差异有统计学意义（ 字2=10.568，P=0.001）；研究组心力衰竭改善总有效率为95.0%，高于对照组的81.7%，比较差异有统计学意义（ 字2=5.175，P=0.023）。结论：胺碘酮联合参松养心胶囊治疗冠心病心律失常疗效显著，毒副作用小，安全性高，值得临床推广。 　　【关键词】 胺碘酮； 参松养心胶囊； 冠心病； 心律失常 　　【Abstract】 Objective：To investigate the clinical observation and safety of Amiodarone combined with Shensong Yangxin Capsule in treatment of coronary heart disease with arrhythmia.Method：A total of 120 patients with arrhythmia in coronary heart disease treated in our hospital from January 2013 to December 2016 were selected.According to the different treatment methods，they were divided into control group and study group，60 cases in each group.The control group was treated with Amiodarone，and study group added Shensong Yangxin Capsule on the basis of control group.The cardiac function index before and after treatment，improvement of arrhythmia and adverse reactions between two groups were compared.Result：After treatment，the stroke volume（SV），cardiac output（CO），cardiac index（CI） and ejection fraction（EF） of two groups were all better than those of before treatment，and study group were all better than those of control group，the differences were statistically significant（P0.05）.The incidence of adverse reactions of study group was 5.0%，which was less than 26.7% of control group，the difference was statistically significant（ 字2=10.568，P=0.001）.The total effective rate of heart failure improvement of study group was 95.0%，which was higher than 81.7% of control group，the difference was statistically significant（ 字2=5.175，P=0.023）.Conclusion：Amiodarone combined with Shensong Yangxin Capsule is effective in the treatment of coronary heart disease with arrhythmia，with small side effects and high safety，w